In the United States approved the first drug for the treatment of patients with suicidal thoughts

Us regulators authorized the use of intranasal spray with esketamine (esketamine) for treatment of patients with clinical depression and suicidal thoughts. Earlier studies have shown that the drug helps to quickly deal with thoughts of suicide and to alleviate the symptoms of depression, says MedicalXpress.

Intranasal spray with esketamine (trade name Stravato) was originally registered with the FDA in March 2019 for use in patients with depression resistant to other therapies. Since the drug was administered at approximately 6, thousand patients.

One of the features of an intranasal spray is fast acting: within 4 hours after application esketamine have noted improvements in the patients ‘ condition. The effect of standard treatment occurs in 6-8 weeks, and this is a very long time, especially if we are talking about the risk of suicide.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]